Crystalys Therapeutics announced a $130M Series B to fund global Phase 3 development and commercialization of dotinurad for gout.
- Amount
- $130M
- Stage
- Series B
- Announced
- 22 July 2026
- Lead
- Frazier Life Sciences
- Other investors
- Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund, Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds
- Use of funds
- Support ongoing late-stage global clinical development and commercialization preparation of dotinurad.
- Checked
- Amount and date checked against the press source